Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$22.54
$29.09
$21.80
▼
$39.71
$458.91M1.15386,709 shs367,967 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$2.38
$2.65
$1.18
▼
$3.11
$464.81M0.221.71 million shs2.17 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$4.07
$5.26
$3.98
▼
$13.15
$404.76M0.851.45 million shs1.83 million shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$4.22
$5.09
$3.93
▼
$8.74
$117.53M1.83921,095 shs1.50 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
0.00%-4.77%-38.42%-22.01%-3.34%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.00%-0.83%-15.00%-8.81%+29.35%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
0.00%-0.25%-27.58%-51.14%-60.52%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
0.00%-10.21%-18.22%-21.27%-8.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$22.54
$29.09
$21.80
▼
$39.71
$458.91M1.15386,709 shs367,967 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$2.38
$2.65
$1.18
▼
$3.11
$464.81M0.221.71 million shs2.17 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$4.07
$5.26
$3.98
▼
$13.15
$404.76M0.851.45 million shs1.83 million shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$4.22
$5.09
$3.93
▼
$8.74
$117.53M1.83921,095 shs1.50 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
0.00%-4.77%-38.42%-22.01%-3.34%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.00%-0.83%-15.00%-8.81%+29.35%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
0.00%-0.25%-27.58%-51.14%-60.52%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
0.00%-10.21%-18.22%-21.27%-8.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.83
Moderate Buy$47.50110.74% Upside
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
2.90
Moderate Buy$6.00152.10% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.50
Moderate Buy$25.00514.25% Upside
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
2.57
Moderate Buy$18.25332.46% Upside

Current Analyst Ratings Breakdown

Latest UNCY, OVID, ASMB, and SPRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/29/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$15.00 ➝ $13.00
9/11/2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/11/2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$4.00 ➝ $5.00
9/8/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$15.00
9/4/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/3/2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$53.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$52.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$52.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$53.00 ➝ $45.00
8/20/2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSpeculative Buy$13.00 ➝ $15.00
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$72.30M6.35N/AN/A$13.04 per share1.73
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$7.25M64.11N/AN/A$1.00 per share2.38
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$84.28M4.80N/AN/A$1.16 per share3.51
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$680K172.83N/AN/A$1.41 per share2.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$6.12M$1.0222.10450.80N/A-0.06%-0.02%-0.02%11/9/2026 (Estimated)
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$17.41M-$0.31N/AN/AN/AN/A-23.64%-20.52%11/11/2026 (Estimated)
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$171.30M-$2.18N/AN/AN/A-184.24%-256.67%-69.63%11/9/2026 (Estimated)
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$26.56M-$1.75N/A2.21N/AN/A-91.50%-61.47%11/11/2026 (Estimated)

Latest UNCY, OVID, ASMB, and SPRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$0.7242-$0.20+$0.5242-$0.20$8.60 million$13.37 million
8/13/2026Q2 2026
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.1150-$0.08+$0.0350-$0.08$0.02 million$0.73 million
8/13/2026Q2 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.4777-$0.63-$0.1523-$0.63$31.32 million$33.66 million
8/12/2026Q2 2026
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$0.4710-$0.06+$0.4110-$0.06$22.22 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
13.99
13.99
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.05
12.39
12.39
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
13.72
3.48
3.28
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
3.81
3.81

Institutional Ownership

CompanyInstitutional Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
72.24%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%

Insider Ownership

CompanyInsider Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
3.50%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
7.00%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.80%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
6.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
7320.36 million19.65 millionOptionable
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
23195.30 million181.63 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
20099.45 million65.83 millionOptionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
2227.85 million26.18 millionNot Optionable

Recent News About These Companies

ROSEN, TRUSTED TRIAL COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
October 4 at 11:13 PM  |  newsfilecorp.comN
Unicycive Therapeutics stock gets a new director as FDA review advances
October 4 at 7:47 PM  |  ad-hoc-news.deA
ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
October 3 at 11:13 PM  |  newsfilecorp.comN
UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
October 3 at 7:44 AM  |  newsfilecorp.comN
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
October 2 at 7:34 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374076/673/en/rosen-national-investor-counsel-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-uncy.html
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
October 2 at 6:17 PM  |  newsfilecorp.comN
Kaplan Fox Class Action Reminder: Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Lead Plaintiff Deadline is November 2, 2026
October 2 at 5:26 PM  |  newmediawire.comN
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Average Rating of "Moderate Buy" from Analysts
October 2 at 4:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077866
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Rated "Moderate Buy" by Wall Street Analysts
October 2 at 4:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-unicycive-therapeutics-inc-nasdaq-uncy-stock-rated-moderate-buy-by-wall-street-analysts-2026-10-02/
Kaplan Fox Reminds Unicycive Therapeutics, Inc. (UNCY) Investors to Seek a Leadership Role Before Deadline on November 2, 2026
October 1, 2026  |  newsfilecorp.comN
DEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373366/3448/en/deadline-alert-for-hyln-hims-uncy-bidu-law-offices-of-howard-g-smith-reminds-investors-of-opportunity-to-lead-securities-fraud-class-actions.html
UNCY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
October 1, 2026  |  newsfilecorp.comN
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373211/9788/en/bronstein-gewirtz-grossman-llc-urges-unicycive-therapeutics-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
October 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/uncy-shareholder-alert-unicycive-therapeutics-inc-securities-class-action-lawsuit---investors-with-losses-may-contact-suewallst-302895636.html
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372752/0/en/unicycive-therapeutics-appoints-meredith-manning-to-board-of-directors.html
HC Wainwright Issues Optimistic Outlook for UNCY Earnings
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073656
HC Wainwright Issues Optimistic Forecast for UNCY Earnings
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-issues-optimistic-forecast-for-uncy-earnings-2026-10-01/
Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Target Cut by HC Wainwright
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31071957
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
September 30, 2026  |  newsfilecorp.comN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY
September 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/levi--korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-november-2-2026-in-unicycive-therapeutics-inc-lawsuit---uncy-302894718.html
Robbins LLP Urges UNCY Stockholders with Significant Losses to Contact the Firm for Information About the Unicycive Therapeutics, Inc. Class Action
September 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/robbins-llp-urges-uncy-stockholders-with-significant-losses-to-contact-the-firm-for-information-about-the-unicycive-therapeutics-inc-class-action-302893640.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Rocket Lab logo overlaid on a rocket standing on a launch pad near the ocean.
Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
By Ryan Hasson | September 12, 2026
Computer screen displaying the Paychex logo over the Paychex Flex payroll and HR dashboard interface on a desk.
Paychex Plunges, Providing the Entry Investors Have Been Waiting For
By Thomas Hughes | September 24, 2026
Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$22.54 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$21.74 -0.80 (-3.54%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$2.38 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$2.40 +0.02 (+1.05%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$4.07 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$4.14 +0.07 (+1.72%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Unicycive Therapeutics stock logo

Unicycive Therapeutics NASDAQ:UNCY

$4.22 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$4.24 +0.03 (+0.59%)
As of 06:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas